目的 探究奥美沙坦酯联合拉贝洛尔治疗原发性高血压患者的临床效果。方法 选取2023年2月—2024年2月在首都医科大学宣武医院诊治的原发性高血压患者141例，随机分为对照组（70例）和治疗组（71例）。对照组患者口服盐酸拉贝洛尔片，100 mg/次，2次/d。治疗组在对照组基础上口服奥美沙坦酯片，20 mg/次，1次/d。两组患者均进行为期8周的治疗。观察两组患者临床疗效，比较治疗前后两组患者血压水平、中医证候评分、杜氏高血压生活质量量表评分、反应性充血指数（RHI）、血清内皮素-1（ET-1）和白细胞介素-6（IL-6）。结果 经治疗，对照组和治疗组患者临床总有效率分别为82.86%、95.77%，两组比较差异具有统计学意义（P＜0.05）。经治疗，两组患者收缩压、舒张压及脉压差均明显低于治疗前（P＜0.05），且治疗组明显低于对照组（P＜0.05）。经治疗，两组患者中医证候评分均大幅度下降，杜氏高血压生活质量量表评分均明显上升（P＜0.05），且治疗组患者的各项评分改善程度均好于对照组（P＜0.05）。经治疗，两组患者RHI水平均较治疗前明显升高，而血清ET-1和IL-6水平均较治疗前明显降低（P＜0.05），且治疗组患者的各项指标改善程度均优于对照组（P＜0.05）。结论 奥美沙坦酯联合拉贝洛尔治疗原发性高血压疗效显著，不仅能够显著降低患者的血压水平，改善临床症状，同时还能够改善患者生活质量并促进内皮功能和血清学指标的修复。

Objective To investigate the effectiveness of olmesartan medoxomil combined with labetalol in treatment of primary hypertension. Methods Patients (141 cases) with primary hypertension in Xuanwu Hospital Capital Medical University from February 2023 to February 2024 were randomly divided into control (70 cases) and treatment (71 cases) group. Patients in the control group were po administered with Labetalol Hydrochloride Tablets, 100 mg/time, twice daily. Patients in the treatment group were po administered with Olmesartan Medoxomil Tablets on the basis of the control group, 20 mg/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluations were evaluated, the blood pressure levels, the traditional Chinese medicine syndrome score and Du's hypertension quality of life scale score, and the levels of RHI, ET-1, and IL-6 in two groups before and after treatment were compared. Results After treatment, the total clinical effective rates in the control group and treatment group were 82.86% and 95.77%, respectively, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the systolic blood pressure, diastolic blood pressure, and pulse pressure differences in two groups were significantly lower than before treatment (P < 0.05), and the pressures in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the TCM syndrome scores in two groups were significantly decreased, and the scores of Du's hypertension quality of life scale score were significantly increased (P < 0.05), and the improvement of various scores in the treatment group was better than that in the control group (P < 0.05). After treatment, the RHI levels in two groups were significantly higher than before treatment, while the serum ET-1 and IL-6 levels were significantly lower than before treatment (P < 0.05), and the improvement of various indicators in the treatment group was better than that in the control group (P < 0.05). Conclusion Olmesartan medoxomil combined with labetalol is highly effective in treating essential hypertension, which can significantly reduce blood pressure, improve symptoms, enhance quality of life, facilitate endothelial function recovery, and reduce serum biomarkers.

R971